Volume 22 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(9): 1479-1482
WANG Yanyan, ZHANG Chao, WANG Lin, PENG Defeng, SUN Siyu, JIANG Fangqian, YANG Qingqing, YAO Tingjing. The correlation between BRAFV600E gene mutations and clinical pathological characteristics of papillary thyroid carcinoma[J]. Chinese Journal of General Practice, 2024, 22(9): 1479-1482. doi: 10.16766/j.cnki.issn.1674-4152.003663
Citation: WANG Yanyan, ZHANG Chao, WANG Lin, PENG Defeng, SUN Siyu, JIANG Fangqian, YANG Qingqing, YAO Tingjing. The correlation between BRAFV600E gene mutations and clinical pathological characteristics of papillary thyroid carcinoma[J]. Chinese Journal of General Practice, 2024, 22(9): 1479-1482. doi: 10.16766/j.cnki.issn.1674-4152.003663
shu

The correlation between BRAFV600E gene mutations and clinical pathological characteristics of papillary thyroid carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003663
  • 1.

    Department of Thyroid and Breast Surgery, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2022AH051420

 2020byzd124

  • Received Date: 2023-11-14
    Abstract
  •   Objective  Papillary thyroid carcinoma (PTC) is a common malignant tumor. The incidence rate is increasing year by year, and its pathogenesis and clinical characteristics are still not very clear. This article intends to explore the relationship between the BRAFV600E gene mutation detection results and the clinicopathological characteristics of PTC patients, so as to provide a basis for treatment decisions of PTC patients.  Methods  According to strict inclusion criteria, eligible case data were collected from patients with papillary thyroid carcinoma admitted to the First Affiliated Hospital of Bengbu Medical University from January 2022 to September 2022. Chi-square test and logistic analysis were used to analyze the BRAFV600E gene mutation and its relationship with clinical and pathological characteristics in PTC patients. All clinical data were statistically analyzed using SPSS 26.0 software.  Results  This study included 108 patients with papillary thyroid carcinoma, with a BRAFV600E gene mutation rate of 70.37% (76/108). The results of univariate analysis showed that the presence of Hashimoto's thyroiditis, central lymph node metastasis, capsule invasion, and maximum diameter of tumor ≥0.5 cm were associated with BRAFV600E gene mutations, and the difference was statistically significant (P < 0.05). The logistic analysis results showed that age ≥55 years and maximum diameter of tumor ≥0.5 cm were risk factors for BRAFV600E mutation, while Hashimoto's thyroiditis was a protective factor for BRAFV600E mutation.  Conclusion  BRAFV600E detection has a certain diagnostic value in papillary thyroid carcinoma. The results of BRAFV600E detection are correlated with some clinical and pathological features of papillary thyroid carcinoma. The results of BRAFV600E detection have good guiding significance for clinical treatment decision-making and prognosis judgment.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    ŚMIECH M, LESZCZYŃSKI P, KONO H, et al. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks[J]. Genes, 2020, 11(11): 1342. doi: 10.3390/genes11111342
    [2]
    HUANG K, GAO N N, BIAN D L, et al. Associations of BRAFV600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma[J]. Exp Ther Med, 2020, 20(6): 243.
    [3]
    LU S Y, CHEN Y C, FENG J L, et al. BRAF Detection of V600E in fine-needle aspiration samples of thyroid nodules by droplet digital PCR[J]. Int J Endocrinol, 2022, 2022: 6243696. DOI: 10.1155/2022/6243696.
    [4]
    XUE N Y, LI P, DENG H D, et al. The spoke wheel color Doppler blood flow signal is a specific sign of papillary thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2022, 13: 1030143. DOI: 10.3389/fendo.2022.1030143.
    [5]
    VACCARELLA S, LORTET-TIEULENT J, COLOMBET M, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(3): 144-152. doi: 10.1016/S2213-8587(20)30401-0
    [6]
    WEI X, WANG X, XIONG J, et al. Risk and prognostic factors for BRAFV600E mutations in papillary thyroid carcinoma[J]. Biomed Res Int, 2022, 2022: 9959649. DOI: 10.1155/2022/9959649.
    [7]
    PILLAI S, GOPALAN V, SMITH R A, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: an update of its clinicopathological features and molecular biology[J]. Crit Rev Oncol Hematol, 2015, 94(1): 64-73. doi: 10.1016/j.critrevonc.2014.12.001
    [8]
    HARAHAP A S, SUBEKTI I, PANIGORO S S, et al. Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS mutational status, and clinicopathological characteristics of papillary thyroid carcinoma in Indonesian national referral hospital[J]. Appl Clin Genet, 2023, 16: 99-110. doi: 10.2147/TACG.S412364
    [9]
    薛丽琼, 郭晔, 陈立波. 晚期甲状腺癌靶向药物不良反应管理专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33(9): 879-888.

    XUE L Q, GUO Y, CHEN L B. Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer(2023 edition)[J]. China Oncology, 2023, 33(9): 879-888.
    [10]
    姬巍, 董健, 昌红, 等. 甲状腺乳头状癌患者临床病理特征和BRAFV600E基因突变对其颈部淋巴结转移的影响[J]. 吉林大学学报(医学版), 2022, 48(4): 995-1002.

    JI W, DONG J, CHANG H, et al. Influence of chinicopathological characteristics and BRAFV600E gene mutation in cervical lymph node metastasis in patients with papillary thyroid cancer[J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 995-1002.
    [11]
    ÖZÇELIK S, BIRCAN R, SARIKAYA Ş, et al. BRAFV600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure[J]. Endokrynologia Polska, 2019, 70(5): 401-408. doi: 10.5603/EP.a2019.0025
    [12]
    KIM M H, BAE J S, LIM D J, et al. Quantification of BRAFV600E alleles predicts papillary thyroid cancer progression[J]. Endocr Relat Cancer, 2014, 21(6): 891-902. doi: 10.1530/ERC-14-0147
    [13]
    刘燕, 曹广磊, 陈丽. 超声引导下细针穿刺和BRAF~(V600E)分子检测在甲状腺癌诊断中的价值[J]. 山东大学学报(医学版), 2022, 60(10): 57-61.

    LIU Y, CAO G L, CHEN L. Ultrasound-guided fine needle aspiration biopsy and BRAFV600E molecular detection in the diagnosis of thyroid cancer[J]. Journal of Shandong University (Health Science), 2022, 60(10): 57-61.
    [14]
    GALÁN-GARCÍA M E, MARTÍNEZ-MARTIN M S, ARAUJO-RUANO E J, et al. Thyroid fine needle aspiration, the bethesda system, and the BRAFV600E mutation in papillary thyroid carcinoma: association and prediction for biopsy[J]. Acta Cytologica, 2023, 67(4): 346-356. doi: 10.1159/000528860
    [15]
    杨元芳, 赵焕, 郝莉. 分化型甲状腺癌患者术后复发转移的临床指标及相关影响因素分析[J]. 实用癌症杂志, 2022, 37(10): 1619-1621, 1631. doi: 10.3969/j.issn.1001-5930.2022.10.013

    YANG Y F, ZHAO H, HAO L. Analysis of Clinical Indexes and Related Influencing Factors of Postoperative Recurrence and Metastasis in Patients with Differentiated Thyroid[J]. The Practical Journal of Cancer, 2022, 37(10): 1619-1621, 1631. doi: 10.3969/j.issn.1001-5930.2022.10.013
    [16]
    LEE J H, KIM Y, CHOI J W, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3): 343-349. doi: 10.1530/EJE-12-0903
    [17]
    LIANG J, ZENG W, FANG F, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients[J]. Acta Otorhinolaryngol Ital, 2017, 37(5): 393-400. doi: 10.14639/0392-100X-1709
    [18]
    谭碧星, 李丽, 李佩佩, 等. 桥本氏甲状腺炎背景下甲状腺乳头状癌BRAFV600E突变及侵袭性分析[J]. 医学影像学杂志, 2023, 33(9): 1666-1669.

    TAN B X, LI L, LI P P, et al. Study on BRAFV600E mutation and invasiveness in papillary thyroid carcinoma under the background of Hashimoto's thyroiditis[J]. Journal of Medical Imaging, 2023, 33(9): 1666-1669.
    [19]
    孙敬, 郝鹏宇, 张贝, 等. 甲状腺乳头状癌不同临床特征和BRAFV600E突变率的对比研究[J]. 生物医学转化, 2021, 2(4): 85-92.

    SUN J, HAO P Y, ZHANG B, et al. Comparative study of different clinical characteristics and BRAFV600E mutation rate in papillary thyroid carcinoma[J]. Biomedical Transformation, 2021, 2(4): 85-92.
    [20]
    ENUMAH S, FINGERET A, PARANGI S, et al. BRAFV600E mutation is associated with an increased risk of papillary thyroid cancer recurrence[J]. World J Surg, 2020, 44(8): 2685-2691. doi: 10.1007/s00268-020-05521-2
    [21]
    雷威, 李慧, 马志强. 甲状腺乳头状癌患者术前超声联合BRAF基因对淋巴结分期的诊断价值[J]. 中华全科医学, 2022, 20(6): 1007-1011. doi: 10.16766/j.cnki.issn.1674-4152.002511

    LEI W, LI H, MA Z Q. Diagnostic value of preoperative ultrasound combined with BRAF gene in lymph node staging in patients with papillary thyroid carcinoma[J]. Chinese Journal of General Practice, 2022, 20(6): 1007-1011. doi: 10.16766/j.cnki.issn.1674-4152.002511
    [22]
    NECHIFOR-BOILA A, ZAHAN A, BANESCU C, et al. Impact of BRAFV600E mutation on event-free survival in patients with papillary thyroid carcinoma: a retrospective study in a romanian population[J]. Cancers (Basel), 2023, 15(16): 4053. DOI: 10.3390/cancers15164053.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (24) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return